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Evaluation of genetic causes of cardiomyopathy in childhood*
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Abstract Cardiomyopathy frequently has a genetic basis. In adults, mutations in genes encoding components of the
sarcomere, cytoskeleton, or desmosome are frequent genetic causes of cardiomyopathy. Although children share these
causes, ~30% of children have an underlying metabolic, syndromic, or neuromuscular condition causing their
cardiomyopathy, making the aetiologies more diverse in children as compared with adults. Although some children
present with obvious signs or symptoms of metabolic, syndromic, or neuromuscular disease, other cases may be quite
subtle, requiring a high level of suspicion in order to diagnose them. In general, the younger the child, the more
extensive the differential. Advantages of identifying the underlying genetic cause of cardiomyopathy in the paediatric
population include conﬁrming the diagnosis in ambiguous cases, facilitating appropriate surveillance and manage-
ment of cardiac and extra-cardiac diseases, providing prognostic information, and establishing the genetic basis in the
family, thereby allowing the identiﬁcation of at-risk relatives and institution of appropriate family screening as
indicated. For these reasons, genetic testing is increasingly recognised as standard of care, and guidelines for genetic
counselling, testing, and incorporation of family-based risk assessment have been established. Therapies aimed at
treating speciﬁc genetic aetiologies of cardiomyopathy are emerging and are exciting new developments that require
increasingly sophisticated approaches to diagnosis. As genetic testing capabilities continue to expand technically,
careful interpretation, knowledgeable clinical utilisation, and appropriate dissemination of genetic information are
important and challenging components of clinical care.
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Aetiology of paediatric cardiomyopathy
An aetiological classiﬁcation of cardiomyopathy was
presented by the Pediatric Cardiomyopathy Registry
(PCMR) in 2000, in which the following ﬁve major
categories were identiﬁed: familial, metabolic,
syndromic, neuromuscular, and idiopathic.1–4 In
addition, infectious causes are an important cause of
dilated cardiomyopathy and heart failure. Data
demonstrate that the prognosis varies depending on
the aetiological category.1,4–6 The most common
causes within each category are shown in Table 1.
Familial cardiomyopathy
The term “Familial” as an aetiological class for car-
diomyopathy typically implies an underlying patho-
genic sarcomeric or cytoskeletal gene variant. The
term is somewhat of a misnomer as, for example,
Noonan syndrome is heritable and, therefore, may
lead to an autosomal dominant family history of
hypertrophic cardiomyopathy. In addition, “familial”
cases may result from de novo mutations arising for
the ﬁrst time in the patient. Although these patho-
genic variants are heritable, the proband is the ﬁrst in
the family with the mutation, and thus there would
not be a family history upon presentation. In the last
*Presented at Johns Hopkins All Children’s Heart Institute, International
Pediatric Heart Failure Summit, Saint Petersburg, Florida, United States of
America, 4–5 February, 2015.
Correspondence to: S. M. Ware, Departments of Pediatrics and Medical and
Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana,
United States of America. Tel: + 1-317-274-8938; Fax: + 1-317-274-8679;
E-mail: stware@iu.edu
Cardiology in the Young (2015), 25(Suppl. 2), 43–50 © Cambridge University Press, 2015
doi:10.1017/S1047951115000827
http://dx.doi.org/10.1017/S1047951115000827
Downloaded from http:/www.cambridge.org/core. Open University Libraryy, on 23 Dec 2016 at 21:16:13, subject to the Cambridge Core terms of use, available at http:/www.cambridge.org/core/terms.
decade, it has been increasingly recognised that
pathogenic variants or mutations in the cardiac
sarcomere, cytoskeleton, desmosome, and nuclear
envelope give rise to an important subset of paediatric
cardiomyopathy cases, including disease in infants.7–9
In a single-centre study of consecutive unrelated
paediatric cardiomyopathy patients by Kindel et al,
42% of the cases had a familial aetiology based
on molecular testing and/or Mendelian inheritance
pattern within the pedigree.9 The genetic testing for
familial cardiomyopathy has been recently reviewed.10
Neuromuscular disease and cardiomyopathy
Neuromuscular disease is commonly associated
with cardiomyopathy. Mutations in genes that are
Table 1. Genetic causes of paediatric cardiomyopathy.
Category Cause
Gene examples
(non-comprehensive) Phenotype Inheritance
“Familial”
Sarcomeric genes MYH7, MYBPC3, MYL2, MYL3,
TNNT2, TNNI3, TNNC1,
MYH6, TPM1, ACTC1, etc.
HCM, DCM, RCM, LVNC Autosomal dominant
Cytoskeletal genes TTN, CSRP3, TCAP, VCL,
ACTN2, DES, LDB3, SGCD,
MYPN, ANKRD1, BAG3,
NEBL, NEXN, etc.
HCM, DCM, RCM Autosomal dominant
Desmosomal genes DSP, PKP2, DSG2, DSC2, JUP,
etc.
ARVC, DCM Autosomal dominant
Nuclear envelope genes LMNA DCM Autosomal dominant
Metabolic
Fatty acid oxidation disorders
(trifunctional protein,
VLCAD, LCHAD),
ACADVL, HADHA, HADHB,
etc.
HCM, DCM, LVNC Autosomal recessive
Carnitine abnormalities
(carnitine acylcarnitine
translocase deﬁciency,
carnitine palmitoyltransferase
deﬁciency (CPTII)
SLC25A20, CPT2 DCM Autosomal recessive
Mitochondrial disorders
(including Kearns–Sayre
syndrome, Barth syndrome,
Friedreich’s ataxia)
Mt genome mutations/deletion,
TAZ, FRDA, SCO2, SURF1,
COX genes, ANT1, etc.
HCM, DCM, LVNC Autosomal recessive,
mitochondrial, X-linked
(Barth syndrome)
Organic acidaemias (propionic
acidaemia, etc.)
PCCA, PCCB DCM Autosomal recessive
Storage disorders (glycogen
storage disorders, especially
Pompe syndrome;
mucopolysaccharidoses; Fabry
disease, sphingolipidoses;
haemochromatosis, Danon
disease)
PRKAG2, LAMP2, GLA, GAA,
AGL, etc.
HCM Autosomal recessive,
X-linked (Danon
disease)
Syndromic
RASopathies (Noonan,
Costello,
Cardiofaciocutaneous, Noonan
with multiple lentigenes, etc.)
PTPN11, RAF1, SOS1, KRAS,
HRAS, BRAF, NRAS, MAP2K1,
MAP2K2, CBL, SHOC2
HCM Autosomal dominant;
high de novo mutation
rate
Alstrom syndrome ALMS1 DCM Autosomal recessive
Neuromuscular
Muscular dystrophies
(Duchenne, Becker, limb
girdle, Emery– Dreifuss,
congenital muscular
dystrophy, etc.), myotonic
dystrophy, myoﬁbrillar
myopathy
DMD, DMPK, EMD, LMNA,
FHL1, FKRP, FLNC, LGMD2A,
LGMD2B, LGMD2C,
LGMD2D, LGMD2E, etc.
DCM Autosomal dominant,
X-linked (DMD, EMD)
ARVC= arrhythmogenic right ventricular cardiomyopathy; DCM= dilated cardiomyopathy; HCM= hypertrophic cardiomyopathy; LVNC= left
ventricular non-compaction cardiomyopathy; RCM= restrictive cardiomyopathy
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important for the functioning of both skeletal and
cardiac muscles result in both myopathy and cardio-
myopathy. The classic examples of neuromuscular
diseases associated with cardiomyopathy are Duch-
enne and Becker muscular dystrophy. In Duchenne
muscular dystrophy, an X-linked condition, boys
typically present in childhood with clumsiness,
weakness, and progressive difﬁculty with ambula-
tion. They typically develop evidence of cardiomyo-
pathy in adolescence, but great variability in age of
onset exists, and there is much interest in better
understanding the genotype–phenotype correlations
that might predict the severity of cardiac involve-
ment.11 Cardiac surveillance is indicated beginning
with the establishment of the diagnosis of Duchenne
muscular dystrophy. Likewise, carrier females of
Duchenne muscular dystrophy mutations are at risk
for dilated cardiomyopathy in adulthood and require
ongoing cardiac screening. Other myopathies that
have cardiac involvement include Emery–Dreifuss
muscular dystrophy, inherited as an autosomal
dominant or X-linked condition and classically
characterised by a triad of joint contractures, weak-
ness, and wasting – especially in a humero–peroneal
distribution – and cardiac involvement including
dilated cardiomyopathy and heart failure. The cardiac
features classically present in the second decade.
Limb girdle muscular dystrophies are a genetically
heterogeneous group of disorders that share weakness
of limbs, greater in the proximal than in the distal
limbs, and muscle wasting. Many LGMD are asso-
ciated with cardiomyopathy, and cardiac surveillance
is indicated at the time of diagnosis. It is unusual for
cardiomyopathy to be the initial presenting feature in
these disorders; however, elevations in creatine
phosphokinase levels should prompt further evalua-
tion for an underlying myopathy if a diagnosis has
not been made. Myotonic dystrophy, myoﬁbrillar
myopathies, and congenital myopathies can all have
cardiac involvement as well, typically with dilated
cardiomyopathy and heart failure.
Friedreich’s ataxia is a neuromuscular disorder that
is characterised by hypertrophic cardiomyopathy
initially, although dilated cardiomyopathy and heart
failure may occur in later stages of disease.12 Caused
most commonly by a bi-allelic triplet repeat expan-
sion in intron 1 of the gene encoding Frataxin, the
age of onset of Friedreich’s ataxia varies depending on
the size of the repeat and residual protein expression.
The initial signs are typically clumsiness, falling, and
ataxia. Although the symptoms of Friedreich’s ataxia
are neuromuscular, Friedreich’s ataxia can also prop-
erly be considered a mitochondrial disorder as its
pathogenesis is related to defective mitochondrial
function resulting from impaired iron handling and
abnormal accumulation of intra-mitochondrial iron.
Metabolic disease and cardiomyopathy
The exact incidence of inborn errors of metabolism
associated with cardiomyopathy is uncertain. Initial
reports quoted 5%,13 but more recent small studies
have demonstrated incidences of 16% of dilated car-
diomyopathy and 36% of hypertrophic cardiomyo-
pathy,12 with a second study showing an overall
incidence of 13.5%.14 The term inborn error of
metabolism refers to diseases caused by defects in
proteins encoded by genes important for intermediary
metabolism or energy production (Table 1). Inborn
errors of metabolism are important to recognise causes
of cardiomyopathy in children because there are spe-
ciﬁc treatments for many of them. In addition, they are
associated with medical problems in other organ sys-
tems that need sub-specialist care. Most inborn errors
of metabolism are inherited in an autosomal recessive
manner; therefore, recurrence risk estimates within a
family differ from “familial” cases of cardiomyopathy.
If caused by an autosomal recessive inborn error of
metabolism, the recurrence risk would be 25%,
whereas autosomal dominant familial cardiomyopathy
has a recurrence risk of 50%. Mitochondrial disorders
may have an autosomal recessive inheritance pattern if
caused by a mutation in the nuclear genome, or
exhibit mitochondrial inheritance if caused by a
mutation in the mitochondrial genome. Although
individual inborn errors of metabolism are quite rare,
as an aggregate, they occur in approximately 1 in
4000 individuals and are likely an underappreciated
cause of cardiomyopathy in childhood.15
The major categories of inborn errors of metabo-
lism associated with paediatric cardiomyopathy are
shown in Table 1 and include disorders of fatty acid
oxidation, carnitine transport, storage disorders,
organic acidaemias, congential disorders of glycosy-
lation, and mitochondrial disorders. Typical signs
and symptoms associated with these inborn errors of
metabolism include hypotonia, developmental delay,
hypoglycaemia, acidosis or other evidences of meta-
bolic derangement, liver involvement, or evidence of
storage such as hepatomegaly or coarse features.
Pathognomonic biochemical abnormalities are iden-
tiﬁable in speciﬁc disorders, but it must be remem-
bered that metabolic screening represents a snapshot
in time, and false negatives can be seen. The meta-
bolic ﬁndings in speciﬁc disorders have been the
subject of a recent review.15
Newborn screening has increased the ascertainment
of some inborn errors of metabolism for which there
are risks of cardiomyopathy. The American College of
Medical Genetics has recommended a core panel of
disorders for inclusion in newborn screening, and this
includes fatty acid oxidation disorders, propionic
acadaemia, and carnitine-uptake deﬁciency;16,17
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however, mitochondrial disorders, lysosomal
disorders, congenital disorders of glycosylation, and
glycogen storage disorders are not on current panels.
Similar to the metabolic screening described above,
false negatives can also occur on newborn screening. In
addition, depending on the timing of each states’
implementation of screening, some children and
adolescents with cardiomyopathy have not been
screened. As therapy exists for a number of these
inborn errors of metabolism – for example, enzyme-
replacement therapy for Pompe disease – an early and
accurate diagnosis is essential.
Although some children present signiﬁcant extra-
cardiac signs and symptoms associated with their
inborn error of metabolism, in others, the diagnosis
requires a high degree of suspicion. There is evi-
dence that some inborn errors of metabolism can
present later in childhood acutely, with cardio-
myopathy as the only symptom of disease, suggest-
ing that ongoing consideration of these disorders in
the differential of cardiomyopathy in childhood is
warranted.18,19 Cardiomyopathy is a relatively
common presenting symptom of mitochondrial
disorders, and hypertrophic cardiomyopathy, dila-
ted cardiomyopathy, and left ventricular
non-compaction cardiomyopathy have all been
described.20 As an example of the subtlety of these
disorders, an 8-year-old child with hypertrophic
cardiomyopathy without outﬂow tract obstruction
recently presented after an extensive evaluation at an
outside hospital. His medical history was unre-
markable, except for attention deﬁcit disorder
diagnosed at the relatively young age of 3. His
evaluation leading to the diagnosis of hypertrophic
cardiomyopathy occurred after the electro-
cardiogram performed before tonsillectomy
demonstrated bradycardia and left ventricular
hypertrophy, prompting a diagnostic evaluation.
His physical examination was unremarkable except
for his cardiac examination, and importantly his
neurological and musculoskeletal evaluations were
normal. His previous testing included normal
genetic panel testing for familial causes of hyper-
trophic cardiomyopathy, normal urine organic
acids, normal acylcarnitine proﬁle, normal urine
glycosaminoglycans, and genetic testing for Pompe
disease. By report, cardiac biopsy was concerning for
storage material, but review of pathology was not
immediately available. Tests for lactate, pyruvate,
and serum amino acids were ordered. Surprisingly,
his lactate level was 12.9 mmol/L and alanine con-
centrations in the serum were also elevated, con-
sistent with the elevated lactate level. Review of his
cardiac biopsy scanning electron micrographs
showed evidence of marked mitochondrial pro-
liferation (Fig 1), with some mitochondrial
irregularity. The sarcomeres were grossly abnormal.
Based on these ﬁndings, a mitochondrial disorder
was suspected, and sequencing of the mitochondrial
genome showed a mutation – m.3303C>T in
tRNAleu. The mutation had been previously
described in a number of individuals with hyper-
trophic cardiomyopathy. The diagnosis sub-
stantially impacted care, as the patient required
surveillance for a number of other medical problems
potentially associated with mitochondrial disorders.
In addition, speciﬁc metabolic precautions were
instituted during stressful events such as illness,
dehydration, or surgery. Finally, risk assessment for
family members and the requirement for familial
cardiac surveillance could be precisely determined
by testing for the mitochondrial mutation in at risk
individuals.
Figure 1.
Cardiac biopsy scanning electron micrograph in a patient with a
mitochondrial disorder. The patient had a mutation in the
mitochondrial genome, tRNALeu. On the scanning electron micrograph,
many inter-myoﬁbrillar and sub-sarcolemmal mitochondrial aggregates
were observed. Pathological mitochondria included those with
paracrystalline inclusions, thumbprint-like cristae, smudged matrix,
and cristae dense inclusions.
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Genetic syndromes and cardiomyopathy
There are over 100 genetic syndromes in which car-
diomyopathy has been described, and the underlying
genetic causes of these syndromes are increasingly
recognised; one of the most common genetic syn-
dromes associated with hypertrophic cardiomyopathy
is the Noonan syndrome. Part of a larger group of
RASopathies that include Cardiofaciocutaneous syn-
drome, Costello syndrome, and Noonan syndrome
with multiple lentigenes – previously known as the
LEOPARD syndrome – among others, the Noonan
syndrome is classically characterised by short stature,
dysmorphic features, and cardiac involvement con-
sisting of cardiovascular malformations, hypertrophic
cardiomyopathy, or both. 21,22 Patients with Noonan
syndrome are at risk for learning disability. In addi-
tion, they are at increased risk for a number of med-
ical problems, and health supervision guidelines exist
to guide appropriate management and surveillance.23
For this reason, it is important to diagnose patients
with Noonan syndrome as early as possible. Noonan
syndrome is inherited as an autosomal dominant
condition, but there is a high de novo rate. As ﬁrst-
degree relatives of patients with de novo mutations
are not at risk for cardiomyopathy, cardiac screening
would not be required. Genotype–phenotype
correlations exist for Noonan syndrome – for exam-
ple, PTPN11 mutations are more strongly associated
with cardiovascular malformations, whereas RAF1
mutations are associated with hypertrophic
cardiomyopathy.
Alstrom syndrome is an underrecognised syn-
drome associated with dilated cardiomyopathy.
Infants with Alstrom syndrome may present with
dilated cardiomyopathy in infancy but without any
other evidence of a syndromic condition.24,25 Often,
dilated cardiomyopathy will resolve only to recur
during adolescence.26,27 Other medical complica-
tions in Alstrom syndrome are age-related in onset
and include sensorineural hearing loss and retinal
dystrophy leading to blindness. Patients with
Alstrom syndrome also have ﬁndings similar to
metabolic syndromes including obesity, hyper-
insulinaemia, early onset type 2 diabetes, and
hypertriglyceridaemia. Alstrom syndrome is inher-
ited in an autosomal recessive pattern.
Genetic and metabolic evaluation
Owing to the signiﬁcant heterogeneity of causes of
paediatric cardiomyopathy, evaluation by a geneti-
cist knowledgeable in cardiac genetics is important.
In general, the younger the child, the larger the
differential due to limited history and medical
information. The parameters for establishing a
diagnosis of cardiomyopathy have been well-
described. For dilated cardiomyopathy, additional
testing should include complete blood count, renal
and liver function tests, assessment of levels of
creatine phosphokinase, lactate, pyruvate, plasma
amino acids, urine organic acids, and an acylcarni-
tine proﬁle (Table 2). The yield of testing by next-
generation sequencing panels for familial dilated
cardiomyopathy is ~25%. Additional genetic and
enzymatic testing may be useful. Cardiac catheter-
isation and endomyocardial biopsy are not routine
but may be useful in patients with acute dilated
cardiomyopathy. Biopsy samples can also be asses-
sed for the presence of mononuclear cell inﬁltrates,
myocardial damage, storage abnormalities, and
viral infection or genomes. It is considered standard
of care to screen ﬁrst-degree family members using
echocardiography and echocardiography in idio-
pathic and familial cases.28
In hypertrophic cardiomyopathy, the electro-
cardiogram typically demonstrates left ventricular
hypertrophy with ST segment and T-wave abnormal-
ities. Intra-ventricular conduction delays and signs of
ventricular pre-excitation (Wolff–Parkinson–White
syndrome) may be present and should raise the possi-
bility of Danon disease – X-linked, caused by LAMP2
mutations – or Pompe disease – autosomal recessive,
caused by GAA mutations. Echocardiography is
Table 2. Suggested evaluation of cardiomyopathy in childhood: non-cardiac parameters.
Detailed family history: minimum three generation pedigree; update at each visit
History and physical: with attention to developmental history, school performance, other chronic medical problems, growth, dysmorphic
features, muscle strength and tone, neurologic exam, vision, hearing
Initial laboratory testing considerations
Metabolic: serum amino acids, urine organic acids, acylcarnitine proﬁle, lactate, pyruvate, electrolytes, and glucose, CPK
Genetic: consideration of next-generation sequencing panel for cardiomyopathy or appropriate genetic testing for genetic syndromes based on
evaluation
Recommendation/facilitation of cardiac imaging in ﬁrst-degree family members
Genetic counselling
CPK= creatine phosphokinase
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diagnostic in identifying, localising, and quantifying
the degree of myocardial hypertrophy. Additional
diagnostic studies in hypertrophic cardiomyopathy
patients include metabolic testing, genetic testing for
speciﬁc syndromic conditions, or genetic testing for
mutations in genes known to cause isolated hyper-
trophic cardiomyopathy. The clinical availability of
these tests is expanding rapidly and the yield of testing
is quite high for hypertrophic cardiomyopathy
(50–75%). As with dilated cardiomyopathy, it is
considered standard of care to perform cardiac screen-
ing and ongoing surveillance in all ﬁrst-degree family
members for idiopathic or familial cases.
Restrictive cardiomyopathy, left ventricular non-
compaction cardiomyopathy, and arrhythmogenic
right ventricular cardiomyopathy are relatively rare
in the paediatric population. Nevertheless, they
exhibit the same degree of heterogeneity with regard
to cause as hypertrophic cardiomyopathy and dilated
cardiomyopathy.1,4,5 Molecular diagnostic rates
using currently available genetic testing are not
known with certainty.
Cascade screening: family-based care
The present consensus guidelines recommend cardiac
screening and known mutation testing for indivi-
duals at-risk of developing cardiomyopathy; however,
the clinical impact of these recommendations is lar-
gely unknown.28–33 A recent study of the uptake of
cardiac screening and genetic testing amongst ﬁrst-
and second-degree relatives at-risk for hypertrophic
cardiomyopathy or dilated cardiomyopathy indicated
an uptake rate of 57 and 39%, respectively.34 Not
surprisingly, ﬁrst-degree relatives were more likely to
complete cardiac screening and genetic testing than
second-degree relatives. When the proband was
mutation positive and both cardiac screening and
known mutation testing were recommended, rela-
tives were more likely to complete cardiac screening.
The number of living affected individuals in a family
also impacted the uptake of cardiac screening. In this
study, cascade cardiac screening found that 25% of
identiﬁed at-risk ﬁrst- and second-degree relatives
had cardiomyopathy that was asymptomatic and
previously undiagnosed. Genetic testing led to the
identiﬁcation of 22 asymptomatic at-risk relatives for
whom ongoing cardiac surveillance was indicated.
Known familial mutation testing also identiﬁed 33
not-at-risk individuals. Relatives who tested negative
for the known familial mutations could be re-assured
about the potential risk of disease and ongoing car-
diac surveillance could be discontinued. In addition,
children of these individuals could be spared genetic
testing and cardiac screening.
It should be emphasised that family histories are
dynamic, and the indications of testing for affected
family members change as new individuals in the
family are diagnosed. Therefore, it is important to
address family history at each clinic visit and update
screening recommendations accordingly. Increas-
ingly, clinicians are being called to incorporate
family-based care into medical practice, thus treating
the entire family rather than a single individual. This
is paradigm-altering in medical practice and has
signiﬁcant implications to the responsibilities and
clinical encounters.
Timing of cardiac screening and
genetic testing
The timing of genetic testing and cardiac screening
needs to be carefully considered for each patient and
family. As in other genetic diseases, testing the most
severely affected family member before initiating
known mutation testing in at-risk relatives is
recommended.28,29,31 In the case of a symptomatic
relative, or a relative participating in potentially
high-risk activities such as competitive athletics,
cardiac screening before completion of genetic testing
in the proband may be indicated to ensure optimal
safety.30 If no aetiology is identiﬁed, all ﬁrst-degree
relatives should undergo routine cardiac screening. If
relatives are diagnosed with disease, subsequent
relatives should undergo screening based on the cas-
cade approach. If a disease-causing mutation is
identiﬁed, all the affected relatives and ﬁrst-degree
unaffected relatives should be offered genetic coun-
selling and genetic testing. Recommendations for
genetic testing and cardiac screening are unique to
each family and depend upon accurate interpretation
of results by professionals with expertise in molecular
genetics. An important beneﬁt of establishing a cause
of cardiomyopathy in a family is risk stratiﬁcation for
potentially affected family members. A cascade
approach to genetic testing in family members is
likely to lead to signiﬁcant cost savings but future
studies are warranted to further deﬁne the beneﬁt.
Implications for clinical practice
The genetic basis of cardiomyopathy in childhood is
complex. An accurate and precise diagnosis is
important to better direct patient management,
including extra-cardiac management, and to assess
risk to family members. Genetic testing for cardio-
myopathy is increasingly available. The yield of
testing continues to increase, but the interpretation
of results is also becoming more complex. Accurate
interpretation of genetic test results is necessary to
make appropriate recommendations for cardiac
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screening, and genetic testing and should be carried
out in the context of the family history. It is not
uncommon to identify more than one genetic variant
in a proband and/or a variant of uncertain signiﬁcance
making interpretation more complicated. Fre-
quently, family-based cardiac screening recommen-
dations may not routinely be discussed and/or genetic
testing may not be offered in a standardised manner.
In addition, this increasingly brings new scenarios for
which most physicians have little training, such as
the disclosure of family-based information. It is
important that paediatric cardiologists receive train-
ing in clinical genetics to facilitate appropriate
referral and testing. Further, there is an urgent need
for more genetics professionals, including genetic
counsellors and geneticists, with cardiac disease-
speciﬁc knowledge. Developing the appropriate
infrastructure to increasingly incorporate genetics in
the care of patients and families is an important goal.
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